- Condition: Bladder Cancer
Intervention: Drug: Gemcitabine and Cisplatin (DD GC)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Conditions: Squamous Cell Carcinoma; Head and Neck Cancer
Intervention: Biological: EGFR Antisense DNA
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; University of Pittsburgh
Not yet recruiting - verified May 2012 - Condition: Lung Cancer
Intervention: Drug: LDE225, Etoposide and Cisplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Cancer of Head and Neck
Intervention: Biological: GL-ONC1
Sponsors: Genelux Corporation; Genelux Corporation
Recruiting - verified April 2012 - Condition: Small Cell Lung Carcinoma
Interventions: Drug: BAY1000394; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Head and Neck Neoplasms
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Drug: nab-paclitaxel; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Chemoradiation; Radiation: Chemoradiation; Procedure: Quality-of-life assessment
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Radiation: Proton Beam Radiation; Drug: Cisplatin; Drug: Etoposide
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified March 2012 - Condition: Head and Neck Cancer
Interventions: Drug: Intra-arterial cisplatin; Drug: Intravenous cisplatin
Sponsors: Southern Illinois University; Southern Illinois University
Not yet recruiting - verified April 2012 - Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical CancerCondition: Cervical Cancer
Interventions: Radiation: Intensity Modulated Radiation Therapy (IMRT); Drug: Cisplatin
Sponsors: University of California, San Diego; University of California, San Diego; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Cervical Carcinoma
Interventions: Radiation: Intensity Modulated Radiation Therapy (IMRT); Drug: Cisplatin; Drug: Gemcitabine
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified March 2012 - Condition: Lung Cancer
Interventions: Drug: Afatinib; Radiation: Radiation; Drug: Cisplatin; Drug: Pemetrexed; Procedure: Surgery
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified March 2012 - Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Drug: Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan); Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan); Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12); Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
Sponsors: University of Iowa; University of Iowa; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Cystic Fibrosis
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; University of Southern California; University of Minnesota - Clinical and Translational Science Institute; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Amgen; AstraZeneca; Eli Lilly and Company; Johnson & Johnson; Merck; Pfizer; Critical Path Institute; Predictive Safety Testing Consortium
Recruiting - verified March 2012 - Condition: Cancer of the Cervix
Interventions: Drug: Granisetron; Drug: Ondansetron; Behavioral: Questionnaires; Behavioral: Study Drug Diary
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sancuso
Recruiting - verified March 2012 - Condition: Oropharyngeal Neoplasms
Interventions: Drug: Docetaxel; Drug: Cisplatin; Drug: Flourouracil; Radiation: External beam radiation therapy/ Intensity modulated RT; Drug: Cisplatin; Drug: Carboplatin
Sponsors: North Shore Long Island Jewish Health System; Bhoomi Mehrotra
Recruiting - verified February 2012 - Condition: Urothelial Carcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Ipilimumab
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bristol-Myers Squibb
Recruiting - verified March 2012 - Conditions: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Oropharyngeal Neoplasms
Interventions: Radiation: Intensity Modulated Radiotherapy (IMRT); Drug: Cisplatin; Procedure: Limited surgical evaluation
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; University of Florida
Recruiting - verified February 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: paclitaxel; Drug: cisplatin/carboplatin
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258; Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: Placebo; Drug: cisplatin/carboplatin; Drug: paclitaxel
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012 - Conditions: Solid Tumors; Bladder Cancer
Interventions: Drug: Gemcitabine + Cisplatin + Dovitinib; Drug: Gemcitabine + Carboplatin + Dovitinib
Sponsors: Mount Sinai School of Medicine; Matthew Galsky; Novartis
Recruiting - verified March 2012 - Condition: Small Cell Lung Cancer
Interventions: Drug: Cisplatin; Drug: Cisplatin
Sponsors: University of Florida; University of Florida
Recruiting - verified December 2011 - Condition: Cervical Cancer
Interventions: Drug: Nelfinavir; Drug: Cisplatin; Radiation: Pelvic External Beam Radiation Therapy; Radiation: Brachytherapy; Procedure: Pharmacokinetic Sampling; Procedure: Cervical Biopsy; Procedure: Pelvic Examination; Procedure: Pap Smear; Procedure: Audiogram; Procedure: Proctoscopy; Procedure: Cytoscopy; Procedure: Renal Ultrasound; Procedure: CT Scan; Procedure: Whole Body PET/CT Scan
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting - verified December 2011 - Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: Taxotere; Drug: Xeloda; Drug: Cisplatin
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified December 2011 - Condition: Germ Cell Cancer
Interventions: Other: Endo-PAT2000 testing; Other: Endo-PAT2000 testing
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011 - Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011 - Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Urologic Neoplasms; Metastatic Bladder Cancer; Urinary Tract Neoplasms
Interventions: Drug: OGX-427 600 mg; Drug: OGX-427 1000 mg; Drug: Placebo
Sponsors: OncoGenex Technologies; OncoGenex Technologies; OncoGenex Pharmaceuticals; PRA International
Recruiting - verified May 2012 - Condition: Mesothelioma
Interventions: Drug: SS1P; Drug: Pemetrexed; Drug: Cisplatin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Lung Cancer; Head and Neck Cancer; Hearing Loss; Ototoxicity; Tinnitus; Neuropathy
Interventions: Drug: SPI-1005 Low Dose; Drug: SPI-1005 Middle dose; Drug: SPI-1005 High Dose; Drug: Placebo
Sponsors: Sound Pharmaceuticals, Incorporated; Sound Pharmaceuticals, Incorporated; VA Puget Sound Health Care System
Not yet recruiting - verified October 2011 - Condition: Lung Cancer
Interventions: Drug: pemetrexed plus cisplatin; Drug: vinorelbine and docetaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Eli Lilly and Company
Recruiting - verified January 2012 - Conditions: Ureteral Neoplasms; Urinary Bladder Neoplasms; Urethral Neoplasms
Interventions: Drug: Lenalidomide; Drug: Cisplatin; Drug: Gemcitabine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Head and Neck Cancer
Interventions: Drug: Cisplatin; Drug: Carboplatin; Drug: Cetuximab; Drug: Taxane
Sponsors: Stanford University; Stanford University; Varian Medical Systems
Recruiting - verified April 2012 - Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Drug: MEDI-551; Drug: Rituximab; Drug: ICE; Drug: DHAP; Procedure: Autologous Stem Cell Transplant (ASCT)
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Drug: Docetaxel; Drug: Cisplatin; Drug: Cetuximab; Drug: Carboplatin
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012 - Condition: Neoplasms
Interventions: Drug: Gemcitabine; Drug: BAY80-6946; Drug: Cisplatin; Drug: NaCl; Drug: BAY80-6964 fixed dose
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Conditions: Cervical Cancer; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexuality and Reproductive Issues
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Recurrent Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Drug: cisplatin; Drug: etoposide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Melanoma
Interventions: Drug: Ipilimumab; Drug: Temozolomide; Drug: Cisplatin; Drug: Interferon Alfa-2b; Drug: Interleukin-2
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified February 2012 - Condition: Head and Neck Cancer
Interventions: Drug: CUDC-101; Drug: Cisplatin; Radiation: Radiation Therapy
Sponsors: Curis, Inc.; Curis, Inc.
Recruiting - verified May 2012 - Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cabazitaxel 10mg/m2; Drug: Cabazitaxel 12.5mg/m2; Drug: Experimental: Cabazitaxel 15mg/m2; Drug: Experimental: Cabazitaxel 17.5mg/m2; Drug: Cabazitaxel 20mg/m2
Sponsors: Mount Sinai School of Medicine; Krzysztof Misiukiewicz; Sanofi-Aventis; Mount Sinai School of Medicine
Recruiting - verified November 2011 - Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung; Nonsmall Cell Lung Cancer Stage III
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Radiation: Radiation Therapy; Drug: Pemetrexed; Drug: Cisplatin; Radiation: Radiation Therapy; Procedure: Lobectomy; Procedure: Lobectomy
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Recruiting - verified June 2011 - Condition: Esophageal Cancer
Interventions: Drug: Paclitaxel with Cisplatin; Drug: Arm B
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified June 2011 - Condition: Cancer
Interventions: Procedure: Insertion of Pressure Equalization (PE) Tubes; Drug: Sodium Thiosulfate (STS); Other: Saline (Placebo); Drug: Cisplatin
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified January 2012 - Condition: Head and Neck Cancer
Interventions: Drug: Cisplatin; Radiation: Elective Nodal Irradiation (ENI)
Sponsors: New Hanover Regional Medical Center; New Hanover Regional Medical Center; National Cancer Institute (NCI); Coastal Carolina Radiation Oncology (CCRO)
Recruiting - verified June 2011 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Oral palonosetron; Drug: I.V. palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011 - Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: DCA (dichloroacetate); Drug: Placebo
Sponsors: Sanford Health; Sanford Health
Recruiting - verified May 2012 - Conditions: Cervical Squamous Cell Carcinoma; Adenosquamous Carcinoma; Adenocarcinoma; Locally Advanced Malignant Neoplasm; Cervical Cancer
Interventions: Procedure: Extraperitoneal laparoscopic lymphadenectomy (EPLND); Radiation: Chemoradiation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Conditions: Advanced or Metastatic Solid Tumors; Previously Untreated Gastric Cancer
Interventions: Drug: E7050; Drug: cisplatin; Drug: capecitabine
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: acupressure therapy; Procedure: sham intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Lung Cancer
Intervention: Biological: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Metastatic Urothelial Carcinoma
Intervention: Drug: Lenalidomide
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; Celgene Corporation
Recruiting - verified October 2011 - Conditions: Solid Tumors; Non-Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Panobinostat, Cisplatin, Pemetrexed
Sponsors: University of California, Davis; University of California, Davis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Stage III Non-small Cell Lung Cancer
Intervention: Drug: Chemotherapy following concurrent Chemoradiotherapy
Sponsors: Louisiana State University Health Sciences Center Shreveport; Syed Jafri
Recruiting - verified April 2012 - Conditions: Transitional Cell Carcinoma of Bladder; Urethra Cancer; Ureter Cancer; Malignant Tumor of Renal Pelvis
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Biological: ALT-801
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: HER-2 Gene Amplification
Interventions: Drug: Cisplatin, Capecitabine, Trastuzumab and MM-111; Drug: Lapatinib, Trastuzumab and MM-111; Drug: Paclitaxel, Trastuzumab and MM-111
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified March 2012 - Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: carboplatin-Taxol regimen; Drug: cisplatin; Drug: paclitaxel; Procedure: adjuvant therapy; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Interventions: Drug: S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm); Drug: Fluorouracil/cisplatin (control arm)
Sponsors: Taiho Pharma USA, Inc.; Taiho Pharma USA, Inc.
Recruiting - verified April 2012 - Conditions: Salivary Gland Squamous Cell Carcinoma; Stage II Salivary Gland Cancer; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: Radiation: intensity-modulated radiation therapy; Drug: cisplatin; Radiation: image-guided adaptive radiation therapy; Other: 3'-deoxy-3'-[18F]fluorothymidine; Procedure: positron emission tomography/computed tomography; Radiation: fludeoxyglucose F 18
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Bladder Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Lung Cancer; Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Cervical Cancer
Interventions: Drug: cisplatin; Drug: paclitaxel; Drug: veliparib; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: ICM plus Olaparib; Drug: ICM without Olaparib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Lung Cancer, Small Cell
Interventions: Drug: pazopanib; Drug: pemetrexed
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Advanced Cancers; Sarcoma
Interventions: Procedure: Hyperthermic Peritoneal Perfusion (HIPEC); Drug: Cisplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Intervention: Drug: raltegravir and cisplatin
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance; American Cancer Society
Recruiting - verified February 2012 - Condition: Urothelial Carcinoma
Intervention: Drug: Gemcitabine and Cisplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral CavityConditions: Squamous Cell Carcinoma (SCC) of the Oral Cavity; Squamous Cell Carcinoma of the Soft Palate
Interventions: Biological: LI plus CIZ; Other: Standard of Care (SOC); Biological: LI + SOC
Sponsors: CEL-SCI Corporation; CEL-SCI Corporation; Teva Pharmaceutical Industries; Orient Europharma Co., Ltd.
Recruiting - verified January 2012 - Conditions: Carcinoma, Non-Small-Cell Lung; Urinary Bladder Neoplasms
Intervention: Drug: Carbon-14-labeled carboplatin
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified December 2011 - Conditions: Solid Tumor; Anaplastic Thyroid Cancer
Interventions: Drug: Cisplatin and Crolibulin; Drug: Cisplatin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Cixutumumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Transitional Cell Carcinoma; Bladder Carcinoma; Urothelial Carcinoma
Interventions: Drug: Everolimus; Drug: Everolimus; Drug: Paclitaxel
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012 - Conditions: Lung Cancer; Non Small Cell Lung Carcinoma; Hypermethylation
Interventions: Drug: Cisplatin; Drug: Carboplatin; Drug: Paclitaxel; Drug: Vidaza; Procedure: Tumor Specimen for Methylation Analysis; Procedure: Blood Sample for Methylation Analysis; Drug: Vinorelbine; Drug: Docetaxel; Drug: Pemetrexed
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified October 2011 - Condition: Urothelial Cancer
Intervention:
Sponsors: University of Chicago; University of Chicago
Recruiting - verified June 2011 - Condition: Ovarian Carcinoma
Intervention: Drug: SJG-136
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Melanoma (Skin)
Interventions: Drug: cisplatin; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: temozolomide; Drug: vinblastine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Breast Cancer
Intervention: Drug: Sorafenib
Sponsors: Emory University; Emory University; Onyx Pharmaceuticals; Bayer
Recruiting - verified April 2012 - Condition: Cancer
Interventions: Drug: Trametinib (GSK1120212); Drug: Docetaxel; Drug: Erlotinib; Drug: Pemetrexed; Drug: Carboplatin; Drug: nab-Paclitaxel; Drug: Cisplatin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Bladder Cancer; Renal Pelvis Cancer; Ureter Cancer
Intervention: Drug: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Neuroblastoma
Interventions: Drug: busulfan; Drug: cisplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: isotretinoin; Drug: melphalan; Drug: topotecan hydrochloride; Drug: vincristine sulfate; Other: pharmacological study; Other: questionnaire administration; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: iobenguane I 131
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Pancreatic Neoplasms; Pancreatic Cancer
Interventions: Drug: Gemcitabine and cisplatin; Drug: Gemcitabine / Cisplatin
Sponsors: Emory University; Emory University
Recruiting - verified May 2012 - Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast CancerCondition: Breast Neoplasms
Intervention: Drug: Platinum based chemotherapy, radiation, surgery
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011 - Conditions: Pleural Metastases; Breast Cancer; Colon Cancer; Ovarian Cancer; Uterine Cancer; Renal Cell Cancer; Thymic Cancer
Intervention: Procedure: Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center
Recruiting - verified September 2011 - Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Cetuximab; Drug: Cetuximab; Drug: Docetaxel; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Radiotherapy (RT); Other: Chemotherapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Cholangiocarcinoma; Hepatobiliary Neoplasm; Liver Cancer; Bile Duct Cancer; Cancer of Gallbladder
Interventions: Procedure: Stereotactic Body Radiotherapy; Drug: Gemcitabine100 mg/m2; Drug: Cisplatin; Drug: Carboplatin; Drug: Capecitabine; Drug: 5FU
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011 - Condition: Head and Neck Cancer
Interventions: Drug: Everolimus escalating dose; Drug: Everolimus or Placebo
Sponsors: University of Chicago; University of Chicago; Novartis Pharmaceuticals
Recruiting - verified June 2011 - Condition: Cancer
Intervention: Drug: Panitumumab
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Amgen
Recruiting - verified February 2012 - Condition: Thrombocytopaenia
Interventions: Drug: Eltrombopag olamine; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Other: radiation combined with weekly carboplatin; Procedure: conservation surgery
Sponsors: Southern Illinois University; Southern Illinois University
Recruiting - verified March 2012 - Conditions: Estrogen Receptor-negative Breast Cancer; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Other: immunohistochemistry staining method; Genetic: gene expression analysis; Drug: veliparib; Drug: cisplatin; Drug: vinorelbine tartrate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Non Small Cell Lung Cancer
Intervention: Drug: Nelfinavir
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012 - Condition: Head and Neck Neoplasms
Interventions: Drug: Cetuximab; Drug: Cisplatin; Drug: 5 - Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Advanced Solid Tumors
Interventions: Dietary Supplement: calcitriol; Drug: cisplatin; Drug: gemcitabine hydrochloride; Other: pharmacological study
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Conditions: Thymoma; Thymic Carcinoma
Interventions: Drug: Belinostat; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Head and Neck Neoplasms
Interventions: Drug: Pemetrexed; Drug: Cetuximab; Drug: Carboplatin; Drug: Cisplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified October 2011 - Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Cisplatin; Drug: Rucaparib; Drug: Cisplatin
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Clovis Oncology, Inc.
Recruiting - verified March 2012 - Conditions: Head and Neck Cancer; Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cisplatin; Drug: Docetaxel; Drug: Erlotinib; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Conditions: Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: Drug: vorinostat; Drug: cisplatin; Radiation: radiation therapy; Other: laboratory biomarker analysis; Genetic: protein expression analysis; Procedure: biopsy; Genetic: polymerase chain reaction; Genetic: DNA methylation analysis; Other: immunohistochemistry staining method; Other: immunoenzyme technique; Other: fluorescence activated cell sorting; Other: flow cytometry
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; National Comprehensive Cancer Network
Recruiting - verified November 2011 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: RAD001 (in addition to standard radiation and chemotherapy)
Sponsors: University of Chicago; University of Chicago; Novartis Pharmaceuticals
Recruiting - verified June 2011 - Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone; Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2012 - Condition: Locally Advanced Non-small Cell Lung Cancer
Intervention: Drug: vorinostat
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Comprehensive Cancer Network
Recruiting - verified June 2011 - Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Intervention: Drug: single arm dose dense MVAC
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center
Recruiting - verified March 2012 - Conditions: Thymoma; Clinical Masaoka Stage II-IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified January 2012 - Conditions: Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: cisplatin; Drug: carboplatin; Other: questionnaire administration
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Cervical Cancer
Interventions: Radiation: intracavitary balloon brachytherapy; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy treatment planning/simulation; Radiation: 3-dimensional conformal radiation therapy; Drug: Cisplatin
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012 - Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: temsirolimus; Drug: cisplatin; Drug: cetuximab
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified March 2012 - Conditions: Lung Cancer; Sarcoma
Intervention: Drug: Cisplatin
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012 - Conditions: Brain Cancer; Choroid Plexus Tumors
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Dactinomycin; Drug: Doxorubicin; Drug: Etoposide; Drug: Irinotecan; Drug: Leucovorin; Drug: Methotrexate; Drug: Temozolomide; Drug: Vincristine
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified April 2012 - Conditions: Breast Cancer; Colorectal Cancer; Myeloma; Chemotherapy-induced Peripheral Neuropathy
Interventions: Behavioral: Questionnaire; Behavioral: Sensory Tests; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: doxorubicin-eluting beads; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: OFATUMUMAB + DHAP; Drug: RITUXIMAB + DHAP
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Triple Negative Breast Cancer
Intervention: Drug: Temsirolimus, cisplatin, erlotinib
Sponsors: Columbia University; Columbia University; Wyeth is now a wholly owned subsidiary of Pfizer; Genentech
Recruiting - verified October 2011 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Pemetrexed, Cisplatin, Bevacizumab
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Head and Neck Neoplasms
Interventions: Drug: Docetaxel/cisplatin; Radiation: Radiotherapy; Drug: Carboplatin
Sponsors: University of Vermont; University of Vermont
Recruiting - verified March 2012 - Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: mitomycin C
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: GDC-0941; Drug: paclitaxel; Drug: pemetrexed; Drug: cisplatin
Sponsors: Genentech; Genentech
Recruiting - verified November 2011 - Condition: Head and Neck Cancer
Intervention: Other: bevacizumab, cisplatin, cetuximab, radiation therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified January 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel; Drug: Placebo in combination with cisplatin and docetaxel or paclitaxel
Sponsors: BioNumerik Pharmaceuticals, Inc.; BioNumerik Pharmaceuticals, Inc.
Recruiting - verified January 2011 - Condition: Non Small Cell Lung Cancer
Interventions: Radiation: FLT PET; Drug: Neoadjuvant Docetaxel and Cisplatin
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2011 - Condition: Liver Cancer
Interventions: Radiation: yttrium Y 90 glass microspheres; Drug: Cisplatin; Drug: Mitomycin; Drug: Doxorubicin
Sponsors: Northwestern University; Northwestern University; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Squamous Cell Carcinoma of Oropharynx
Interventions: Radiation: IMRT; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012 - Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: cisplatin; Drug: everolimus; Drug: paclitaxel; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Small Cell Lung Carcinoma; Malignant Epithelial Neoplasms
Interventions: Drug: (Belinostat) (PDX101); Drug: Cisplatin; Drug: Etoposide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Solid Cancer
Intervention: Drug: cabazitaxel (XRP6258)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: Non Small Cell Lung Cancer; Small Cell Lung Cancer; Thymoma; Thymus Neoplasms
Intervention: Radiation: Esophageal sparing IMRT
Sponsors: Duke University; Duke University
Recruiting - verified September 2011 - Conditions: Stomach Neoplasms; Esophageal Neoplasms
Interventions: Drug: BMS-833923; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified June 2011 - Conditions: Head and Neck Cancer; Cancer of Nasopharynx
Interventions: Drug: docetaxel; Drug: cisplatin; Drug: 5-Fluorouracil; Procedure: Chemoradiation; Drug: Carboplatin; Drug: Cisplatin
Sponsors: Stanford University; A. Dimitrios Colevas
Recruiting - verified October 2011 - Condition: Carcinoma, Squamous Cell
Intervention: Biological: EGFR Antisense DNA
Sponsors: University of Pittsburgh; University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Drug: Cetuximab; Drug: Dasatinib; Drug: Cisplatin; Radiation: Radiation Therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Bristol-Myers Squibb
Recruiting - verified August 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: thiotepa; Drug: vincristine sulfate; Drug: vorinostat; Radiation: Conformal radiation
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Pleural Mesothelioma
Intervention: Drug: Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012 - Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck CancerCondition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: cisplatin; Radiation: intensity-modulated radiation therapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012 - Conditions: Urothelial Cancer; Muscle-invasive Urothelial Carcinoma
Interventions: Drug: Methotrexate; Drug: Doxorubicin; Drug: vinblastine; Drug: cisplatin; Drug: Pegfilgrastim
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Amgen
Recruiting - verified February 2012 - Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Head and Neck Cancer
Interventions: Drug: Panitumumab; Drug: Cisplatin; Radiation: Radiation Therapy
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified January 2012 - Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Drug: docetaxel; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Hepatocellular Carcinoma
Interventions: Radiation: Stereotactic Body Radiation Therapy (SBRT); Procedure: Transcatheter Arterial Chemoembolization (TACE)
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified July 2011 - Condition: Multiple Myeloma
Interventions: Drug: M-VTD-PACE; Drug: TT3-LITE Regimen (L-TT3)
Sponsors: University of Arkansas; University of Arkansas; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil; Procedure: computed tomography; Procedure: positron emission tomography; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Mesothelioma
Intervention: Other: Pemetrexed + Cisplatin or Carboplatin AUC=5 Pleurectomy/decortication (if feasible) Intensity Modulated Radiation Therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Eli Lilly and Company; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Paranasal Sinuses; Squamous Cell Carcinoma
Interventions: Drug: Docetaxel; Drug: 5-Fluorouracil; Drug: Cisplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sanofi-Aventis
Recruiting - verified March 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Osteosarcoma; Malignant Fibrous Histiocytoma (MFH) of Bone
Interventions: Biological: Bevacizumab; Drug: Chemotherapy (Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide)
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genentech; National Institutes of Health (NIH)
Recruiting - verified June 2011 - Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cancer
Interventions: Dietary Supplement: Multivitamin, Vitamin B12, Vitamin B6.; Dietary Supplement: Vitamin B12, Vitamin B6
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011 - Condition: Solid Tumors
Interventions: Drug: MK1775; Drug: gemcitabine; Drug: cisplatin; Drug: carboplatin; Drug: MK1775; Drug: MK1775; Drug: MK1775; Drug: gemcitabine; Drug: cisplatin; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified May 2012 - Condition: Small Cell Lung Cancer
Interventions: Drug: Cisplatin; Drug: Etoposide; Drug: Placebo; Drug: Cisplatin; Drug: Etoposide; Drug: ZD6474
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; AstraZeneca
Recruiting - verified March 2012 - Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Gastroesophageal Junction Adenocarcinoma; Gastric Cancer
Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Sanofi-Aventis; Roche/Genetech; City of Hope National Medical Center; Piedmont Hospital Research Institute (PHRI); Medical College of Wisconsin; Queens Health Network; Weill Medical College of Cornell University; Memorial Cancer Institute, Florida; University of Pittsburgh; Long Island Jewish Medical Center; Nebraska Cancer Specialists Methodist Estabrook Cancer Center
Recruiting - verified January 2012 - Condition: Peritoneal Neoplasms
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide; Drug: sunitinib malate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cisplatin; Drug: eribulin mesylate; Other: pharmacological study
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: Drug: erlotinib hydrochloride; Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Procedure: quality-of-life assessment
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Thymoma
Interventions: Drug: cisplatin and etoposide; Procedure: Surgical Resection; Radiation: Concurrent Radiotherapy
Sponsors: Valley Health System; Valley Health System
Recruiting - verified August 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012 - Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With OsteosarcomaCondition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: radiation therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Condition: Pancreatic Cancer
Interventions: Biological: recombinant interferon alfa; Drug: cisplatin; Drug: gemcitabine hydrochloride; Procedure: hyperthermia treatment
Sponsors: National Cancer Institute (NCI); The University of Texas Health Science Center, Houston
Recruiting - verified December 2008 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cisplatin; Drug: cytarabine; Drug: dexamethasone; Drug: gemcitabine hydrochloride; Other: clinical observation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: lomustine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Hospital of Philadelphia
Recruiting - verified June 2009
 |
Cisplatin Clinical Trials |
